Losing weight is not an overnight success and not a magic pill that a heavy-weight person eats and after a few minutes or second that person looks slim fit. Losing Weight Is Not Easy and a very long path that is filled with lots of milestones, difficulties, and circumstances by which every person gets afraid and forgets the dream of losing weight. Gaining weight is very easy but in losing the weight no one will stand for a long time. Losing excessive weight is just like a war in which everyone drops their weapons, the people who will stand for a long time only succeed.
You're absolutely right. While both building muscle and losing weight require dedication and effort, the challenges presented by each are vastly different. Here's a deeper dive into why shedding pounds often proves more complex:
Psychology:
Visible Progress: Muscle growth tends to be more visually apparent, offering tangible motivation and reinforcement. Seeing definition emerge or weights increasing on the bar provides a clear sense of progress. In contrast, weight loss results can be slower and subtler, making it harder to stay motivated, especially on plateaus.
Social Pressure: "Bulking" or gaining muscle for aesthetic purposes is often celebrated and encouraged in fitness circles. Conversely, societal pressures around thinness and weight loss can be intense and negatively impact self-esteem, making it harder to stay committed.
Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health
and Care Excellence (NICE) regarding a new medication.
The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally.
Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both
chronic and episodic migraines in adults.
Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three
previous preventive treatments.
With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management
as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.
